Genentech’s Seven Arguments For Saving Avastin: The Commissioner’s Point-By-Point Rebuttal
This article was originally published in RPM Report
Executive Summary
After describing why Genentech’s Avastin in metastatic breast cancer meets the qualifications for withdrawal, FDA Commissioner Margaret Hamburg turned her decision memo to address whether to exercise discretion. Hamburg’s comments on each of Genentech’s seven arguments are a must-read for other pharma sponsors.
You may also be interested in...
How to Withdraw a Drug: FDA’s Final Decision on Avastin
The “streamlined withdrawal” process for Avastin in metastatic breast cancer gave Genentech an extra 11 months to prepare for the transition to off-label status. It also gave FDA time to make preparations of its own.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.